Trial
NCT03746249
Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sun Yat-sen University
Collaborators
—
Condition
Hepatocellular Carcinoma
Intervention
Lenvatinib
Why stopped
No participants enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-17